他汀在动脉瘤性蛛网膜下腔出血中的疗效:系统综述与荟萃分析
该系统综述与荟萃分析纳入13项随机对照试验,比较他汀组776例与安慰剂组821例动脉瘤性蛛网膜下腔出血患者。结果显示他汀显著降低脑血管痉挛、迟发性缺血性神经功能缺损、迟发性脑缺血及死亡率,但对残疾和神经功能不良预后无显著效果。
要点
- 他汀可显著降低aSAH后脑血管痉挛和DCI的发生风险
- 他汀与死亡率下降相关,RR 0.73(95%CI 0.54-0.98)
- 对残疾、神经功能不良预后及肝酶/肌酶升高的影响不显著
核心结论
- 他汀显著降低aSAH患者的血管痉挛、DIND、DCI发生率和死亡率,提示其对aSAH有效。
研究设计与样本
- 系统综述与随机对照试验荟萃分析,检索PubMed、EMBASE和Cochrane Library。
- 纳入13项研究,他汀组776例,安慰剂组821例。
主要发现
- 他汀显著降低血管痉挛频率(RR 0.76;95%CI 0.63-0.91;P=0.003)。
- 他汀显著降低DIND(RR 0.76;95%CI 0.63-0.91;P=0.003)。
- 他汀显著降低血管痉挛相关DCI(RR 0.49;95%CI 0.32-0.74;P=0.0008)。
- 他汀显著降低死亡率(RR 0.73;95%CI 0.54-0.98;P=0.03)。
- 对残疾(RR 0.92;95%CI 0.71-1.20)和神经功能不良预后(RR 0.75;95%CI 0.45-1.27)无显著效果。
关键数值与推荐
- 血管痉挛RR 0.76(95%CI 0.63-0.91;P=0.003)。
- DIND RR 0.76(95%CI 0.63-0.91;P=0.003)。
- 血管痉挛相关DCI RR 0.49(95%CI 0.32-0.74;P=0.0008)。
- 死亡率RR 0.73(95%CI 0.54-0.98;P=0.03)。
临床怎么用
- 对于aSAH患者,可考虑使用他汀以降低血管痉挛、DCI和死亡风险。
- 对残疾和神经功能预后改善的证据不显著,决策需结合个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is an acute cerebrovascular disease with frequent cerebral vasospasm and delayed cerebral ischemia (DCI). The use of statins for patients with aSAH is controversial. The present study evaluated the efficacy of statins in aSAH-induced vasospasm, DCI, delayed ischemic neurological deficit (DIND), mortality, and other outcomes. METHODS: A literature search was performed in PubMed, EMBASE, and the Cochrane Library. English reports of patients with aSAH who had been treated with statins without combination were included. The outcomes, including cerebral vasospasm, DIND, DCI, mortality, disability, and creatine kinase/alanine aminotransferase/aspartic transaminase elevation, were extracted for meta-analysis. RESULTS: A total of 13 studies, with 776 versus 821 patients treated with statins versus placebo, were retained for the statistical meta-analysis. The results showed that statin administration significantly reduced the frequency of vasospasm (relative risk [RR], 0.76; 95% confidence interval [CI], 0.63-0.91; P = 0.003), DIND (RR, 0.76; 95% CI, 0.63-0.91; P = 0.003), vasospasm-DCI (RR, 0.49; 95% CI, 0.32-0.74; P = 0.0008), and mortality (RR, 0.73; 95% CI, 0.54-0.98; P = 0.03). Statins showed insignificant efficacy in the prevention of disability (RR, 0.92; 95% CI, 0.71-1.20), a neurological poor prognosis (RR, 0.75; 95% CI, 0.45-1.27), and creatine kinase/alanine aminotransferase/aspartic transaminase elevation (RR, 1.90; 95% CI, 0.55-6.50). CONCLUSIONS: Statins significantly reduced the incidence of vasospasm, DIND, DCI, and mortality in individuals with aSAH, suggesting its efficacy in aSAH.
引用
- Shen J, Shen J, Zhu K, et al. Efficacy of Statins in Cerebral Vasospasm, Mortality, and Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. World Neurosurg. 2019. PMID: 31295598. doi:10.1016/j.wneu.2019.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。